LY294002 prevents lipopolysaccharide-induced hepatitis in a murine model by suppressing IκB phosphorylation

ZHIZE CHEN, HUIMIN LIU, SHAOQIN LEI, BO ZHAO and ZHONGYUAN XIA

Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China

Received August 26, 2014; Accepted July 3, 2015

DOI: 10.3892/mmr.2015.4574

Abstract. Although fulminant hepatitis represents a ubiquitous human health problem, there is a lack of effective therapeutic strategies that have few side-effects and the precise mechanisms underlying fulminant hepatitis are not fully understood. Phosphoinositide 3-kinase (PI3K) is a pivotal kinase known to regulate inflammatory responses in hepatic diseases. Although previous research indicates that PI3K is involved in cardiac diseases, including myocardial infarction, it currently remains unclear whether the inhibition of PI3K is essential for ameliorating the severity of lipopolysaccharide (LPS)-induced hepatitis. The aim of the present study was to investigate whether pharmacological blockade of PI3K ameliorates the development of LPS-induced murine acute hepatic injury. A murine model of LPS-induced acute hepatic injury was used to investigate the therapeutic effect of the pan-PI3K inhibitor, LY294002 on murine fulminant hepatitis and to investigate potential underlying mechanisms. The current report presents the in vivo role of LY294002 in protecting the mice from fulminant hepatitis. LY294002 was observed to exert significant protective effects on the liver by reducing the activities of alanine aminotransferase and aspartate aminotransferase, as well as by improving the histological architecture of the liver. In LPS-induced hepatitis, treatment with LY294002 clearly inhibited intrahepatic synthesis of various disease-relevant proinflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-6, IL-1β and interferon-γ. Furthermore, LY294002 was observed to significantly inhibit IκB phosphorylation in LPS-injured mouse liver samples. Therefore, LY294002 may protect the liver from LPS-induced injury by inhibition of the IκB-nuclear factor κ-light-chain-enhancer of activated B cell dependent signaling pathway. Thus, the current report provides evidence that LY294002 exerts potent effects against LPS-induced hepatic injury, indicating its potential therapeutic value for the treatment of acute hepatitis.

Introduction

Hepatic injury, caused by misdirected immune stimulation or viral infection, is a type of acute inflammatory injury characterized by inflammatory infiltration of macrophages, T cells, and neutrophils into liver (1). Although hepatitis represents a ubiquitous human health problem, effective therapeutic strategies with minimal side-effects are lacking and the precise mechanisms underlying hepatitis are not fully understood. There are various mouse models of inflammatory liver injury, which have been established to facilitate functional studies on the mechanisms of hepatic injury. For example, liver failure, induced by either intravenous injection of concanavalin A or by sensitizing mice with D-galactosamine, prior to lipopolysaccharide (LPS) administration, is commonly used as an experimental animal model for mimicking human liver disease (2,3). Liver failure is characterized by an accumulation and activation of macrophages, which are highlighted for being involved in the inflammation process by producing large quantities of tumor necrosis factor (TNF)-α, which leads to a direct hepatotoxic potential (4,5). In addition, TNF is known to mediate intrahepatic induction of inducible NO synthase, which is also significant in acute hepatitis (6).

Inflammation is a pathological condition in which various signaling mechanisms control a complex network of cellular and molecular interactions involving the crosstalk between independent biochemical cascades, which terminate in the activation of gene expression programs for cytokines and chemokines (7). In the canonical pathway, nuclear factor κ-light-chain-enhancer of activated B cell (NF-κB) is present as a latent, inactive IκB-bound complex in the cytoplasm, which prevents it from entering nuclei. When these cells are exposed to stimuli, including LPS, LPS binds to Toll-like receptor-4 and phosphorylates IκB, resulting in its subsequent degradation, which enables NF-κB to be released from IκB and enter the nucleus (8). Numerous stimuli activate NF-κB, including LPS, TNF-α and interleukin (IL)-1, and other physiological and pathological stimuli (9,10). IκB phosphorylation regulates the expression of numerous genes involved in inflammatory responses, including genes encoding proinflammatory cytokines, chemokines, enzymes that generate mediators of inflammation, immune receptors and adhesion molecules (11).
Phosphoinositide 3-kinase (PI3K) is a pivotal kinase known to regulate inflammatory responses in various types of disease (12,13). In recent years, there has been increasing evidence regarding the pan-PI3K inhibitor, LY294002 ameliorating the severity of a series of models of autoimmune diseases, including cecal ligation and puncture-induced sepsis, idiopathic pulmonary fibrosis and colitis-induced cancer (14-16). However, whether the PI3K inhibitor suppresses autoimmune hepatitis remains unclear. Furthermore, pan-PI3K inhibition may promote infarct resolution and prevents adverse cardiac remodeling following myocardial infarction in mice (17). A study using PI3Kγ deficient mice demonstrated a complex contribution of PI3Kγ to reparative angiogenesis in myocardial infarction (18). Although previous research suggested that PI3Kγ inhibitors, such as AS605240, were involved in liver diseases (19), it remains unclear whether pan-PI3K inhibition is essential for ameliorating the severity of LPS-induced hepatitis. In the present study, the therapeutic effect of the pan-PI3K inhibitor, LY294002 on acute hepatitis was investigated using an LPS-induced murine hepatitis model. Our results showed that LY294002 prevented the development of hepatitis stimulated by LPS. These data may define an anti-inflammatory role of LY294002 in immunologically mediated hepatic diseases and may provide a foundation for a novel therapeutic modality for treatment of inflammatory hepatic diseases.

Materials and methods

Reagent and animals. A total of 80 female BALB/c mice (aged, 6-8 weeks) were obtained from Hua Fukang Experimental Animal Center (Beijing, China) and treated with humane care according to the National Institutes of Health Guidelines of China. The mice were housed (five mice per cage) at 23±2˚C under a 12:12 light/dark cycle and allowed free access to food and water. Following an acclimatization period of 1 week, they were divided into four groups, according to body weight. The pan-PI3K inhibitor, LY294002 (Fig. 1) was purchased from Sigma Aldrich (St. Louis, MO, USA).

Establishment of a murine model of LPS-induced hepatitis. The present study was approved by the ethics committee of Renmin hospital of Wuhan university (Wuhan, China). LPS dissolved in saline was administered at a total volume of 100 µl per mouse via i.p. injection. For therapeutic agent treatment, LY294002 (concentration, 40 µM; volume, 10 µl) was administered once by i.p. injection 1 h prior to treatment with the corresponding hepatotoxin in the murine model of LPS-induced hepatitis. Following anesthetization of the mice with 45 mg/kg ketamine (Sigma-Aldrich), serum and liver tissue samples were collected 8 h following LPS treatment. To examine survival rate, the mice were challenged with LPS, however the mice were pretreated with LY294002 1 h prior to LPS treatment. The mice were subsequently monitored every 2 h for survival.

Analysis of liver enzymes. Liver injury in LPS-induced acute hepatitis was quantified by measurement of the serum enzyme activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using an automated procedure with an enzymatic assay (ALT-AST1 Kainos Laboratories, Toyko, Japan).

Histologic examination. Four weeks after immunization, the mice were sacrificed by anesthetization, and their hearts were perfused with normal saline, removed, fixed in 4% buffered formaldehyde (BASO, Taiwan, China), and processed for hematoxylin and eosin (H&E) staining (BASO). Hepatic injury on LPS-induced acute hepatitis was scored on the H&E-stained sections using grades from 0 to 4 as follows: 0, No necrotic infiltrates; 1, small foci of necrotic cells between hepatocytes or necrotic cells surrounding individual hepatocytes; 2, larger foci of 100 necrotic cells or involving 30 hepatocytes; 3, 10% of a hepatic cross-section involved; and 4, 30% of a hepatic cross-section involved (20,21).

ELISA. The concentrations of TNF-α, IL-1β, IFN-γ and IL-6 in plasma samples or lymph node cell suspensions were analyzed by ELISA using commercially available TNF-α (cat. no. F8005A), IL-1β (cat. no. F10091A), IFN-γ (cat. no. F5980A) and IL-6 (cat. no. F7699A) ELISA kits from JingMei Biotech. (Shenzhen, China), according to the manufacturer's instructions.

Western blot analysis. The mice were pre-treated with LY294002 (concentration, 40 µM; volume, 10 µl) 1 h before stimulation with LPS, respectively, for 15, 30, 60 or 90 min. The mice were then sacrificed at different time points (15, 30, 60 or 90 min) to harvest the liver tissues. Protein (20 µg) from each sample was mixed with an equal volume of 2X SDS sample buffer (Beyotime Institute of Biotechnology, Haimen, China), boiled for 5 min and then separated by 10% SDS-polyacrylamide gel electrophoresis. Following electrophoresis, proteins were transferred to polyvinylidene fluoride membranes (EMD, Millipore, Billerica, MA, USA). The membranes were incubated with monoclonal rabbit anti-IκB antibody (cat. no. ab32518; 1:1,000; Abcam, Cambridge, MA, USA), monoclonal mouse anti-phosphorylated (p)-IκB antibody (cat. no. ab12135; 1:1,000; Abcam) or monoclonal mouse anti-GAPDH antibody (cat. no. G9295; 1:50,000; Sigma-Aldrich) at 4˚C overnight. The total IκB and p-IκB protein signal was quantified by scanning densitometry using a Quantity One image analysis system (version 4.6.2; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
**Statistical analysis.** The Mann-Whitney U test was used for evaluation of the severity scores. Parametric data were statistically analyzed by Student's t-test or one-way analysis of variance. Data are presented as means ± standard deviation and P<0.05 was considered to indicate a statistically significant difference.

**Results**

**LY294002 administration exerts therapeutic effects in a mouse model of LPS-induced acute hepatic injury.** Injection of LPS causes hepatic injury, including hepatic necrosis, steatosis and inflammatory infiltration. To estimate the efficacy of LY294002 treatment on acute hepatic liver injury, mice were sacrificed 8 h following an i.p. injection of LPS. Routine histopathology confirmed hepatic injury had been achieved in the murine model of LPS-induced acute hepatitis. Furthermore, the mice treated with LY294002 demonstrated a markedly reduced severity of hepatic necrosis when compared with the LPS-treated mice (Fig. 2A). The pattern of infiltrate was assessed by scoring of H&E stained sections. Treatment with LY294002 significantly alleviated LPS-induced hepatitis in mice, as indicated by the reduction of hepatic necrosis. The histological scores of inflammatory infiltrates for individual mice are presented in Fig. 2B. LY294002 treatment significantly reduced the LPS-induced histopathological hepatic injury in mice (P<0.05). Therefore, treatment with LY294002 significantly alleviated LPS-induced liver injury in mice, as indicated by the reduction of serum aminotransferase (Fig. 2C; P<0.01). Furthermore, reduction in liver enzyme levels by LY294002 treatment correlated with enhanced survival. This protective effect of LY294002 pretreatment was further confirmed by analysis of the survival rate of mice challenged with LPS. Mortality was observed as early as 2 h following LPS administration. However, animals treated with LY294002 showed a statistically significant enhancement in survival rate (P<0.05; Fig. 2D).

**Pan-PI3K inhibitor, LY294002 reduces the production of proinflammatory cytokines.** Proinflammatory cytokines are important in human and animal models of acute liver injury (22). In the present study, the effects of pan-PI3K inhibitor, LY294002 on proinflammatory cytokines in LPS-induced acute hepatitis were analyzed. As shown in Fig. 3A-D, mice injected with LPS demonstrated increased secretion levels of TNF-α, IL-6, IL-1β and IFN-γ in murine liver tissue. Administration of LY294002 in mice following LPS injection resulted in a significant reduction of TNF-α, IL-6, IL-1β and IFN-γ production (Fig. 3A-D; P<0.05). These results indicate that LY294002 treatment suppresses the production of cytokines during inflammation, which may protect the liver from injury.
LY294002 treatment inhibits IkB phosphorylation following LPS injection. Phosphorylation of the inhibitory protein, IkB, enables nuclear translocation and DNA binding of NF-κB during inflammation (23). To gain further insight into the mechanism of LY294002-mediated regulation of inflammation, variation in IkB phosphorylation in the mouse model of LPS-induced hepatitis was analyzed in the present study. As shown in Fig. 4, LY294002 significantly inhibited IkB phosphorylation in the mouse model. The mice were pre-treated with LY294002 (concentration, 40 μM; volume, 10 μl) 1 h before stimulation with LPS for 15, 30, 60 or 90 min. Subsequently, it was observed that LY294002 inhibited IkB phosphorylation from 15 to 90 min following LPS-injection. The difference was statistically significant at 60 min following LPS-injection (Fig. 4; P<0.05).

Toxicity of LY294002. To examine the toxicity of LY294002, the mice were sacrificed following 4 weeks of daily injections.
of LY294002 (concentration, 40 µM; volume, 10 µl) and histopathological analysis of heart, liver, spleen, lung and kidney tissue was performed. As shown in Fig. 5, no significant difference was observed in the histopathology between the LY294002 and the normal control groups (Fig. 5).

Discussion

The current report demonstrates the in vivo role of LY294002 in protecting mice from fulminant hepatitis and investigates the possible underlying mechanisms. In the present report, LY294002 was observed to protect the liver from injury by reducing the activities of ALT and AST, and by improving the histological architecture of the liver. In the mouse model of LPS-induced hepatitis, treatment of LY294002 markedly inhibited intrahepatic synthesis of various disease-relevant proinflammatory cytokines (TNF-α, IL-6, IL-1β and IFN-γ). Furthermore, LY294002 significantly inhibited IκB phosphorylation in the mouse model of LPS-induced hepatitis. Therefore, it was hypothesized that LY294002 may protect the liver from LPS-induced injury by inhibition of the IκB-NF-κB dependent signaling pathway.

As a ubiquitous transcription factor that regulates various genes involved in inflammation and immune responses, NF-κB is normally sequestered in the cytoplasm where it associates with a family of inhibitory proteins, known as IκB (24). In response to external signals, IκB is phosphorylated by the IκB kinase complex, and subsequently degraded through ubiquitin-dependent proteolysis (25). Notably, in the present study, LY294002 administration was observed to decrease the cytoplasmic level of IκB protein in sections of mouse liver tissue following LPS injection. These data indicate that LY294002 may bind to IκB and, therefore, may be involved in stabilizing the NF-κB-IκB complex and tethering NF-κB in the cytosol. Thus, establishing whether LY294002 binds to IκB during LPS-induced NF-κB activation may be significant. In our future studies, the focus will be on the mechanism by which LY294002 regulates NF-κB activity via IκB phosphorylation inhibition.

Proinflammatory cytokines are critical in the process of inflammation, and the increased production of TNF-α, IL-6, IL-1β and IFN-γ has previously been reported to be associated with autoimmune cardiac diseases (26-28). In the current study, injection with LPS resulted in marked intrahepatic increases of TNF-α, IL-6, IL-1β and IFN-γ, which was consistent with previous reports (29). Subsequent LY294002 treatment clearly inhibited the serum protein levels of TNF-α, IL-6, IL-1β and IFN-γ; the T-cell-produced cytokines in LPS-injected mice. The results indicate that LY294002 may protect mice from LPS-induced acute hepatic injury by inhibition of proinflammatory cytokines.

The PI3K/AKT signaling pathway has been shown to be involved in LPS-induced immune cell proliferation, accumulation in the liver and consequently liver damage (30,31). In addition, the activation of PI3K/AKT signaling is key in various autoimmune, inflammatory and allergic processes (32-34). The pan-PI3K inhibitor, LY294002 has demonstrated its favorable anti-inflammatory effects in murine models of certain inflammatory diseases via selectively prohibiting activation of the PI3K/AKT signaling pathway in various immune cell types, which was reflected by the reduction of chemokine-induced AKT phosphorylation in immunological cells following LY294002 treatment (35,36). The present study confirmed that LY294002 effectively mediates the induction and development of LPS-induced hepatitis, which was accompanied by a significant reduction in histopathological hepatic necrosis.

In conclusion, the present study demonstrated the hepatoprotective activity of the compound, LY294002 in a mouse model of LPS-induced liver injury, resembling autoimmune hepatitis. The present study demonstrates that the pan-PI3K inhibitor, LY294002 effectively protects and treats LPS-induced murine hepatitis by targeting PI3K activity and consequently suppressing leukocyte infiltration, as well as immunoregulating the unbalance between pro- and anti-inflammation. The major mechanism of this hepatoprotective efficacy appears to be the inhibition of intrahepatic IκB phosphorylation, which prevents the subsequent synthesis of TNF-α, IL-6, IL-1β and IFN-γ. The findings of the present study may be significant in...
the development of LY294002 as a therapeutic agent for the prevention and treatment of human myocarditis. Consequently, the present study provides a novel insight into the treatment of inflammatory liver diseases, such as autoimmune hepatitis. However, further preclinical and clinical studies using a PI3K inhibition compound, such as LY294002, are required and may be valuable towards the treatment of hepatic injury.

Acknowledgements
The present study was supported by Wuhan Science and Technology, Wuhan, China (grant no. 201306230101081).

References